This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BASi Reinvesting To Meet Client Demand, Adding Jobs

Stocks in this article: BASI

BASi (Bioanalytical Systems Inc.) (NASDAQ: BASI), is expanding its capabilities to meet demand for drug discovery and development services. The company has renovated space at its preclinical toxicology site in Evansville, Ind. and will relocate some research services to West Lafayette, creating several new positions. In addition, BASi also has added state-of-art research instrumentation at its bioanalytical labs at three sites.

BASi is using some proceeds of a $5.5 million public offering in May to make capital improvements and purchase laboratory equipment. The building renovations in Evansville are providing scientists with more flexibility with space for multiple studies.

As a result of the growing demand for discovery services, BASi is relocating its in vivo discovery services in 2012 to its facility in the Purdue Research Park of West Lafayette. Several new positions will be created to staff the laboratories. These studies will provide pharmaceutical companies the information they need to evaluate new compounds in the earliest stages of development.

General manager John Devine Jr., BS, DABT, has been promoted to vice president of non-clinical services to oversee expansion of the in vivo discovery services business.

"John has successfully developed the toxicology service at Evansville consistently growing the business year by year," said BASi president and CEO Anthony S. Chilton Ph.D. "John's focus on customers and his commitment to drive sales have contributed to the success of our contract research services."

The ability to analyze thousands of samples each week has been enhanced with the purchase of several new triple quad mass spectrometry systems. Several AB SCIEX Triple Quad ™ LC/MS/MS have been installed at BASi bioanalytical labs in West Lafayette, Ind., McMinnville, Ore. and Warwickshire, UK.

About BASi

BASi is a drug discovery and development services company providing contract research services and instruments to the world's leading pharmaceutical companies and medical research organizations. The company, based in the Purdue Research Park of West Lafayette, focuses on developing innovative services and products that increase efficiency and reduce the cost of taking new and generic drugs to market. Visit for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs